NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

BlossomHill Therapeutics BLSM

BlossomHill Therapeutics listed on Nasdaq on 7 Aug 2026 and is not in the S&P 500. It is worth $458 million. Its price history starts on 7 Aug 2026. 7 directors have filed with the SEC in the last 12 months (who counts), 2 of them executives. 3 other officers are on file.

CEO
Jingrong Jean Cui
Chair
Yishan Li
Listed
7 Aug 2026 on Nasdaq, IPO filings and terms
Headquarters
San Diego, CA
Market cap
$458M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

BlossomHill Therapeutics' market cap since August 2026

Weekly, up to 13 Nov 2026

Sep 2026OctNov$450M

Board and leadership

Board and officers

Roles filed up to 30 Sep 2026

NameTitle
Directors (7)
Yishan LiExecutive ChairmanExecutive Chairman
Jingrong Jean CuiPresident and CEOPresident and CEO
Sundeep AgrawalDirectorDirector
Bihua ChenDirectorDirector
Carl L. GordonDirectorDirector
Sheila GujrathiDirectorDirector
John P. SchmidDirectorDirector
Officers (3)
Jason A. KeyesChief Financial OfficerLast filed 10 Aug 2026Chief Financial Officer
Vincent Paul LiptakGeneral CounselLast filed 10 Aug 2026General Counsel
Geoffrey Raymond OxnardChief Medical OfficerLast filed 10 Aug 2026Chief Medical Officer

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $15.2 million in 6 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
10 Aug 2026BuyCarl L. GordonDirectorDirectorBuy625,000$10M
10 Aug 2026BuyBihua ChenDirectorDirectorBuy312,500$5.0M
10 Aug 2026BuyJohn P. SchmidDirectorDirectorBuy6,000$96K
10 Aug 2026BuyVincent Paul LiptakGeneral CounselGeneral CounselBuy2,200$35K
10 Aug 2026BuyJason A. KeyesChief Financial OfficerChief Financial OfficerBuy700$11K
7 Aug 2026BuyVincent Paul LiptakGeneral CounselGeneral CounselBuy2,500$40K

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: BlossomHill Therapeutics listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.